How to Prevent Bleeding Without Increased Risk of Thrombotic Events
-
- Natsuaki Masahiro
- Department of Cardiovascular Medicine, Saga University
-
- Morimoto Takeshi
- Department of Clinical Epidemiology, Hyogo College of Medicine
-
- Shiomi Hiroki
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University
-
- Yamamoto Ko
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University
-
- Yamaji Kyohei
- Department of Cardiology, Kokura Memorial Hospital
-
- Watanabe Hirotoshi
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University
-
- Uegaito Takashi
- Department of Cardiology, Kishiwada City Hospital
-
- Matsuda Mitsuo
- Department of Cardiology, Kishiwada City Hospital
-
- Tamura Toshihiro
- Department of Cardiology, Tenri Hospital
-
- Taniguchi Ryoji
- Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center
-
- Inoko Moriaki
- Department of Cardiology, Kitano Hospital
-
- Mabuchi Hiroshi
- Department of Cardiology, Koto Memorial Hospital
-
- Takeda Teruki
- Department of Cardiology, Koto Memorial Hospital
-
- Domei Takenori
- Department of Cardiology, Kokura Memorial Hospital
-
- Shirotani Manabu
- Department of Cardiology, Kindai University Nara Hospital
-
- Ehara Natsuhiko
- Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital
-
- Eizawa Hiroshi
- Department of Cardiovascular Medicine, Kobe City Nishi-Kobe Medical Center
-
- Ishii Katsuhisa
- Department of Cardiology, Kansai Denryoku Hospital
-
- Tanaka Masaru
- Department of Cardiology, Osaka Red Cross Hospital
-
- Inada Tsukasa
- Department of Cardiology, Osaka Red Cross Hospital
-
- Onodera Tomoya
- Department of Cardiology, Shizuoka City Shizuoka Hospital
-
- Nawada Ryuzo
- Department of Cardiology, Shizuoka City Shizuoka Hospital
-
- Shinoda Eiji
- Department of Cardiology, Hamamatsu Rosai Hospital
-
- Yamada Miho
- Department of Cardiology, Hamamatsu Rosai Hospital
-
- Yamamoto Takashi
- Department of Cardiology, Shiga University of Medical Science Hospital
-
- Sakai Hiroshi
- Department of Cardiology, Shiga University of Medical Science Hospital
-
- Toyofuku Mamoru
- Department of Cardiology, Japanese Red Cross Wakayama Medical Center
-
- Tamura Takashi
- Department of Cardiology, Japanese Red Cross Wakayama Medical Center
-
- Takahashi Mamoru
- Department of Cardiology, Shimabara Hospital
-
- Tada Tomohisa
- Department of Cardiology, Shizuoka General Hospital
-
- Sakamoto Hiroki
- Department of Cardiology, Shizuoka General Hospital
-
- Tada Takeshi
- Department of Cardiology, Kurashiki Central Hospital
-
- Kaneda Kazuhisa
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University
-
- Miki Shinji
- Department of Cardiology, Mitsubishi Kyoto Hospital
-
- Aoyama Takeshi
- Division of Cardiology, Shimada Municipal Hospital
-
- Suwa Satoru
- and Department of Cardiology, Juntendo University Shizuoka Hospital
-
- Sato Yukihito
- Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center
-
- Ando Kenji
- Department of Cardiology, Kokura Memorial Hospital
-
- Furukawa Yutaka
- Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital
-
- Nakagawa Yoshihisa
- Department of Cardiology, Shiga University of Medical Science Hospital
-
- Kadota Kazushige
- Department of Cardiology, Kurashiki Central Hospital
-
- Kimura Takeshi
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University
書誌事項
- タイトル別名
-
- Bleeding Outcomes After Percutaneous Coronary Intervention in the Past Two Decades in Japan ― From the CREDO-Kyoto Registry Cohort-2 and Cohort-3 ―
この論文をさがす
説明
<p>Background: Optimal intensity is unclear for P2Y12receptor blocker therapy after percutaneous coronary intervention (PCI) in real-world clinical practice.</p><p>Methods and Results: From the CREDO-Kyoto Registry, the current study population consisted of 25,419 patients (Cohort-2: n=12,161 and Cohort-3: n=13,258) who underwent their first PCI. P2Y12receptor blocker therapies were reduced dose of ticlopidine (200 mg/day), and global dose of clopidogrel (75 mg/day) in 87.7% and 94.8% of patients in Cohort-2 and Cohort-3, respectively. Cumulative 3-year incidence of GUSTO moderate/severe bleeding was significantly higher in Cohort-3 than in Cohort-2 (12.1% and 9.0%, P<0.0001). After adjusting 17 demographic factors and 9 management factors potentially related to the bleeding events other than the type of P2Y12receptor blocker, the higher bleeding risk in Cohort-3 relative to Cohort-2 remained significant (hazard ratio (HR): 1.52 95% confidence interval (CI) 1.37–1.68, P<0.0001). Cohort-3 compared with Cohort-2 was not associated with lower adjusted risk for myocardial infarction/ischemic stroke (HR: 0.96, 95% CI: 0.87–1.06, P=0.44).</p><p>Conclusions: In this historical comparative study, Cohort-3 compared with Cohort-2 was associated with excess bleeding risk, which might be at least partly explained by the difference in P2Y12receptor blockers.</p>
収録刊行物
-
- Circulation Journal
-
Circulation Journal 86 (5), 748-759, 2022-04-25
一般社団法人 日本循環器学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390010457708597632
-
- NII論文ID
- 130008106511
- 130008088824
-
- ISSN
- 13474820
- 13469843
-
- Web Site
- http://id.ndl.go.jp/bib/032116673
- https://ndlsearch.ndl.go.jp/books/R000000004-I032116673
- http://id.ndl.go.jp/bib/032116665
- https://ndlsearch.ndl.go.jp/books/R000000004-I032116665
- https://www.jstage.jst.go.jp/article/circj/86/5/86_CJ-21-0784/_pdf
- https://www.jstage.jst.go.jp/article/circj/86/5/86_CJ-21-0526/_pdf
- https://search.jamas.or.jp/link/ui/2023033061
-
- 本文言語コード
- en
-
- 資料種別
- journal article
-
- データソース種別
-
- JaLC
- NDLサーチ
- Crossref
- PubMed
- CiNii Articles
- OpenAIRE
-
- 抄録ライセンスフラグ
- 使用不可